EGFR-binding peptide: a patent evaluation of WO2014002836

Abstract

Peptide ligands have many desirable features enabling them to act as drug molecules and are valuable in the drug discovery processes because of their fewer side effects and great potential to cure diseases. In this patent, three kinds of peptide ligands with 12 – 50 amino acid residues were identified by phase display technology. Some of them not only could be used as potential therapeutic agents for the treatment of EGFR–overexpressed cancers, but also show promising application in detecting cancer tissue or cancer cells that express the EGFR.